Our Team
James W. Larrick, MD, PhD
Dr. James Larrick is a biomedical entrepreneur with an international reputation in biotechnology. He has developed expertise in cytokines, therapeutic antibodies, molecular biology, and pharmaceutical drug development over his thirty-five-year career, and he has written or co-authored nine books, published over 300 papers/chapters, and submitted more than fifty patents.
Dr. Larrick earned his M.D. and Ph.D. from Duke University as a graduate of the prestigious Medical Scientist Training Program. After completing his medical house-staff training at Stanford University, Dr. Larrick contributed to the development of the first therapeutic human monoclonal antibodies for cancer and infectious diseases as a postdoctoral research fellow in the Stanford Cancer Biology Research Labs.
Piero H. Mendez
Piero Mendez is a biomedical engineer with expertise in company formation and early stage drug development. He has founded multiple companies and worked with a number of venture funds focused on biomedical sciences and therapeutics.
Andrew R. Mendelsohn, PhD
Dr. Mendelsohn holds a B.A in Biophysics and Natural Science from the University of Pennsylvania, a PhD in Molecular, Cell biology and Biochemistry from Brown University, performed postdoctoral training at Harvard Medical School and previously was a Research Fellow at Nobel Laureate Sydney Brenner’s innovative organization, Molecular Sciences Institute, which sought to integrate computational and molecular biology.
Keren Ziv, PhD
Dr. Keren Ziv received a PhD from the Weizmann Institute of Science Israel, in the field of cancer angiogenesis and MRI reporter genes. She pursued a postdoctoral fellowship at Stanford, where she conducted research in the field of regenerative medicine and heart diseases in the Molecular Imaging Program (MIPS). Keren has experience in both drug and medical device development.
Among her former roles, she was a senior director at X37, a biotech company using AI for rapid drug discovery, the head of strategic innovation at LevitasBio, a company applying magnet ic levitation technology for cellular analysis, the CSO of CytoMag, developing microfluidic systems for rapid cell isolation, and served as a fellow of Life Science Angels (LSA), medical device and BIO screening committees.
Keren is a board member of the Coulter program at University of Virginia, a translational research program with a mission to support, develop and validate translational research projects that can be widely adopted.